Ceftaroline Fosamil for the Empiric Treatment of Hospitalized Adults with cSSTI: An Economic Analysis from the Perspective of the Spanish National Health System

References

• Christensen KL, Holman RC, Steiner CA, Sejvar JJ, Stoll BJ, Schonberger LB. Infectious disease hospitalizations in the United States. Clin Infect Dis. 2009;49(7):1025–1035. doi:10.1086/605562
   PubMed Web of Science ®Google Scholar
• Suk JE, Semenza JC. Future infectious disease threats to Europe. Am J Public Health. 2011;101(11):2068–2079. doi:10.2105/AJPH.2011.300181
   PubMed Web of Science ®Google Scholar
• Seaton RA, Johal S, Coia JE, Reid N, Cooper S, Jones BL. Economic evaluation of treatment for MRSA complicated skin and soft tissue infections in Glasgow hospitals. Eur J Clin Microbiol Infect Dis. 2014;33(3):305–311. doi:10.1007/s10096-013-1956-z
   PubMed Web of Science ®Google Scholar
• Ostermann H, Blasi F, Medina J, Pascual E, McBride K, Garau J. Resource use in patients hospitalized with complicated skin and soft tissue infections in Europe and analysis of vulnerable groups: the REACH study. J Med Econ. 2014;17(10):719–729. doi:10.3111/13696998.2014.940423
   PubMedGoogle Scholar
• Tun K, Shurko JF, Ryan L, Lee GC. Age-based health and economic burden of skin and soft tissue infections in the United States, 2000 and 2012. PLoS One. 2018;13(11):e0206893–e0206893. doi:10.1371/journal.pone.0206893
   PubMed Web of Science ®Google Scholar
• Kollef MH. Broad-spectrum antimicrobials and the treatment of serious bacterial infections: getting it right up front. Clin Infect Dis. 2008;47(Suppl 1):S3–S13. doi:10.1086/590061
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Napolitano LM, Moran GJ, et al. Economic outcomes of inappropriate initial antibiotic treatment for complicated skin and soft tissue infections: a multicenter prospective observational study. Diagn Microbiol Infect Dis. 2014;79(2):266–272. doi:10.1016/j.diagmicrobio.2014.02.013
   PubMed Web of Science ®Google Scholar
• Lipsky BA, Weigelt JA, Gupta V, Killian A, Peng MM. Skin, soft tissue, bone, and joint infections in hospitalized patients: epidemiology and microbiological, clinical, and economic outcomes. Infect Control Hosp Epidemiol. 2007;28(11):1290–1298. doi:10.1086/520743
   PubMed Web of Science ®Google Scholar
• Tarricone R, Aguzzi G, Capone A, et al. How complicated skin and soft tissue infections are treated in Italy: economic evaluation of inpatient intravenous antibiotic treatment in seven hospitals. J Med Econ. 2008;11(2):265–279. doi:10.3111/13696990802113196
   PubMedGoogle Scholar
• Dryden MS. Complicated skin and soft tissue infection. J Antimicrob Chemother. 2010;65(Suppl 3):iii35–iii44. doi:10.1093/jac/dkq302
   PubMed Web of Science ®Google Scholar
• Suaya JA, Mera RM, Cassidy A, et al. Incidence and cost of hospitalizations associated with Staphylococcus aureus skin and soft tissue infections in the United States from 2001 through 2009. BMC Infect Dis. 2014;14:296. doi:10.1186/1471-2334-14-296
   PubMed Web of Science ®Google Scholar
• Zervos MJ, Freeman K, Vo L, et al. Epidemiology and outcomes of complicated skin and soft tissue infections in hospitalized patients. J Clin Microbiol. 2012;50(2):238–245. doi:10.1128/JCM.05817-11
   PubMed Web of Science ®Google Scholar
• Nathwani D, Dryden M, Garau J. Early clinical assessment of response to treatment of skin and soft-tissue infections: how can it help clinicians? Perspectives from Europe. Int J Antimicrob Agents. 2016;48(2):127–136. doi:10.1016/j.ijantimicag.2016.04.023
   PubMed Web of Science ®Google Scholar
• Pulido-Cejudo A, Guzman-Gutierrez M, Jalife-Montano A, et al. Management of acute bacterial skin and skin structure infections with a focus on patients at high risk of treatment failure. Ther Adv Infect Dis. 2017;4(5):143–161. doi:10.1177/2049936117723228
   PubMed Web of Science ®Google Scholar
• Garau J, Ostermann H, Medina J, et al. Current management of patients hospitalized with complicated skin and soft tissue infections across Europe (2010–2011): assessment of clinical practice patterns and real-life effectiveness of antibiotics from the REACH study. Clin Microbiol Infect. 2013;19(9):E377–385. doi:10.1111/1469-0691.12235
   PubMed Web of Science ®Google Scholar
• Friedland HD, O’Neal T, Biek D, et al. CANVAS 1 and 2: analysis of clinical response at day 3 in two Phase 3 trials of ceftaroline fosamil versus vancomycin plus aztreonam in treatment of acute bacterial skin and skin structure infections. Antimicrob Agents Chemother. 2012;56(5):2231–2236. doi:10.1128/AAC.05738-11
   PubMed Web of Science ®Google Scholar
• Garau J, Blasi F, Medina J, McBride K, Ostermann H; group Rs. Early response to antibiotic treatment in European patients hospitalized with complicated skin and soft tissue infections: analysis of the REACH study. BMC Infect Dis. 2015;15:78. doi:10.1186/s12879-015-0822-2
   PubMed Web of Science ®Google Scholar
• Edelsberg J, Berger A, Weber DJ, Mallick R, Kuznik A, Oster G. Clinical and economic consequences of failure of initial antibiotic therapy for hospitalized patients with complicated skin and skin-structure infections. Infect Control Hosp Epidemiol. 2008;29(2):160–169. doi:10.1086/526444
   PubMed Web of Science ®Google Scholar
• Corey GR, Wilcox M, Talbot GH, et al. Integrated analysis of CANVAS 1 and 2: phase 3, multicenter, randomized, double-blind studies to evaluate the safety and efficacy of ceftaroline versus vancomycin plus aztreonam in complicated skin and skin-structure infection. Clin Infect Dis. 2010;51(6):641–650. doi:10.1086/655827
   PubMed Web of Science ®Google Scholar
• Karve S, Hackett J, Levinson J, Gibson E, Battersby A. Ceftaroline fosamil treatment outcomes compared with standard of care among hospitalized patients with complicated skin and soft tissue infections. J Comp Eff Res. 2016;5(4):393–405. doi:10.2217/cer-2015-0024
   PubMed Web of Science ®Google Scholar
• Athanasakis K, Petrakis I, Ollandezos M, et al. Antibacterial treatment of methicillin-resistant Staphylococcus aureus complicated skin and soft tissue infections: a cost and budget impact analysis in Greek hospitals. Infect Dis Ther. 2014;3(2):257–268. doi:10.1007/s40121-014-0044-8
   PubMedGoogle Scholar
• Schurmann D, Sorensen SV, De Cock E, Duttagupta S, Resch A. Cost-effectiveness of linezolid versus vancomycin for hospitalised patients with complicated skin and soft-tissue infections in Germany. Eur J Health Econ. 2009;10(1):65–79. doi:10.1007/s10198-008-0104-7
   PubMed Web of Science ®Google Scholar
• Grau S, Mateu-de Antonio J, Soto J, Marin-Casino M, Salas E. Pharmacoeconomic evaluation of linezolid versus teicoplanin in bacteremia by Gram-positive microorganisms. Pharm World Sci. 2005;27(6):459–464. doi:10.1007/s11096-005-1638-8
   PubMedGoogle Scholar
• Bounthavong M, Zargarzadeh A, Hsu DI, Vanness DJ. Cost-effectiveness analysis of linezolid, daptomycin, and vancomycin in methicillin-resistant Staphylococcus aureus: complicated skin and skin structure infection using bayesian methods for evidence synthesis. Value in Health. 2011;14(5):631–639. doi:10.1016/j.jval.2010.12.006
   PubMed Web of Science ®Google Scholar
• Bassetti M, Baguneid M, Bouza E, Dryden M, Nathwani D, Wilcox M. European perspective and update on the management of complicated skin and soft tissue infections due to methicillin-resistant Staphylococcus aureus after more than 10 years of experience with linezolid. Clin Microbiol Infect. 2014;20(Suppl 4):3–18. doi:10.1111/1469-0691.12463
   PubMed Web of Science ®Google Scholar
• Liu C, Bayer A, Cosgrove SE, et al. Clinical practice guidelines by the infectious diseases society of America for the treatment of methicillin-resistant Staphylococcus aureus infections in adults and children. Clin Infect Dis. 2011;52(3):e18–55.
   PubMed Web of Science ®Google Scholar
• Stevens DL, Bisno AL, Chambers HF, et al. Practice guidelines for the diagnosis and management of skin and soft-tissue infections. Clin Infect Dis. 2005;41(10):1373–1406. doi:10.1086/497143
   PubMed Web of Science ®Google Scholar
• Leong HN, Kurup A, Tan MY, Kwa ALH, Liau KH, Wilcox MH. Management of complicated skin and soft tissue infections with a special focus on the role of newer antibiotics. Infect Drug Resist. 2018;11:1959–1974.
   PubMed Web of Science ®Google Scholar
• Talbot GH, O’Neal T, Das AF, Thye D. Prospective study of the Wilson severity-of-illness scoring system for complicated skin and skin structure infections. Antimicrob Agents Chemother. 2013;57(1):647–650. doi:10.1128/AAC.01344-12
   PubMed Web of Science ®Google Scholar
• Rao N, Gibson E, Lawson R, et al. ZinforoTM (ceftaroline fosamil) versus other empiric initial IV antibiotics for complicated skin and soft tissue infections. Paper presented at: ISPOR2016. Washington, D.C; 2016.
   Google Scholar
• Moran GJ, Fang E, Corey GR, Das AF, De Anda C, Prokocimer P. Tedizolid for 6 days versus linezolid for 10 days for acute bacterial skin and skin-structure infections (ESTABLISH-2): a randomised, double-blind, phase 3, non-inferiority trial. Lancet Infect Dis. 2014;14(8):696–705. doi:10.1016/S1473-3099(14)70737-6
   PubMed Web of Science ®Google Scholar
• Prokocimer P, De Anda C, Fang E, Mehra P, Das A. Tedizolid phosphate vs linezolid for treatment of acute bacterial skin and skin structure infections: the ESTABLISH-1 randomized trial. JAMA. 2013;309(6):559–569. doi:10.1001/jama.2013.241
   PubMed Web of Science ®Google Scholar
• Kauf TL, McKinnon P, Corey GR, et al. An open-label, pragmatic, randomized controlled clinical trial to evaluate the comparative effectiveness of daptomycin versus vancomycin for the treatment of complicated skin and skin structure infection. BMC Infect Dis. 2015;15:503. doi:10.1186/s12879-015-1261-9
   PubMed Web of Science ®Google Scholar
• Lan S-H, Chang S-P, Lai -C-C, Lu L-C, Chao C-M. Ceftaroline efficacy and safety in treatment of complicated skin and soft tissue infection: a systemic review and meta-analysis of randomized controlled trials. J Clin Med. 2019;8(6):776. doi:10.3390/jcm8060776
   PubMed Web of Science ®Google Scholar
• McCool R, Gould IM, Eales J, et al. Systematic review and network meta-analysis of tedizolid for the treatment of acute bacterial skin and skin structure infections caused by MRSA. BMC Infect Dis. 2017;17(1):39. doi:10.1186/s12879-016-2100-3
   PubMed Web of Science ®Google Scholar
• Vlachaki I, Vacchelli M, Zinzi D, et al. Comparative efficacy of delafloxacin for complicated and acute bacterial skin and skin structure infections: results from a network meta-analysis. BMC Infect Dis. 2021;21(1):1036. doi:10.1186/s12879-021-06736-x
   PubMed Web of Science ®Google Scholar
• O’Riordan W, McManus A, Teras J, et al. A comparison of the efficacy and safety of intravenous followed by oral delafloxacin with vancomycin plus aztreonam for the treatment of acute bacterial skin and skin structure infections: a phase 3, multinational, double-blind, randomized study. Clin Infect Dis. 2018;67(5):657–666. doi:10.1093/cid/ciy165
   PubMed Web of Science ®Google Scholar
• Corrado ML. Integrated safety summary of CANVAS 1 and 2 trials: Phase III, randomized, double-blind studies evaluating ceftaroline fosamil for the treatment of patients with complicated skin and skin structure infections. J Antimicrob Chemother. 2010;65(Suppl 4):iv67–iv71. doi:10.1093/jac/dkq256
   PubMed Web of Science ®Google Scholar
• Arbeit RD, Maki D, Tally FP, Campanaro E, Eisenstein BI. The safety and efficacy of daptomycin for the treatment of complicated skin and skin-structure infections. Clin Infect Dis. 2004;38(12):1673–1681. doi:10.1086/420818
   PubMed Web of Science ®Google Scholar
• Konychev A, Heep M, Moritz RK, et al. Safety and efficacy of daptomycin as first-line treatment for complicated skin and soft tissue infections in elderly patients: an open-label, multicentre, randomized phase IIIb trial. Drugs Aging. 2013;30(10):829–836. doi:10.1007/s40266-013-0114-8
   PubMed Web of Science ®Google Scholar
• Martin M, Quilici S, File T, Garau J, Kureishi A, Kubin M. Cost-effectiveness of empirical prescribing of antimicrobials in community-acquired pneumonia in three countries in the presence of resistance. J Antimicrob Chemother. 2007;59(5):977–989. doi:10.1093/jac/dkm033
   PubMed Web of Science ®Google Scholar
• Bosmans JE, Coupé VM, Knottnerus BJ, Geerlings SE, Moll van Charante EP, Ter Riet G. Cost-effectiveness of different strategies for diagnosis of uncomplicated urinary tract infections in women presenting in primary care. PLoS One. 2017;12(11):e0188818. doi:10.1371/journal.pone.0188818
   PubMed Web of Science ®Google Scholar
• Martín-Peña A, Gil-Navarro MV, Aguilar-Guisado M, et al. Cost-effectiveness analysis comparing two approaches for empirical antifungal therapy in hematological patients with persistent febrile neutropenia. Antimicrob Agents Chemother. 2013;57(10):4664–4672. doi:10.1128/AAC.00723-13
   PubMed Web of Science ®Google Scholar
• Kongnakorn T, Eckmann C, Bassetti M, et al. Cost-effectiveness analysis comparing ceftazidime/avibactam (CAZ-AVI) as empirical treatment comparing to ceftolozane/tazobactam and to meropenem for complicated intra-abdominal infection (cIAI). Antimicrob Resist Infect Control. 2019;8:204. doi:10.1186/s13756-019-0652-x
   PubMed Web of Science ®Google Scholar
• Bassetti M, Montero JG, Paiva JA. When antibiotic treatment fails. Intensive Care Med. 2018;44(1):73–75. doi:10.1007/s00134-017-4962-2
   PubMed Web of Science ®Google Scholar
• File, Jr TM Jr, Low DE, Eckburg PB, et al. Integrated analysis of FOCUS 1 and FOCUS 2: randomized, doubled-blinded, multicenter phase 3 trials of the efficacy and safety of ceftaroline fosamil versus ceftriaxone in patients with community-acquired pneumonia. Clin Infect Dis. 2010;51(12):1395–1405. doi:10.1086/657313
   PubMed Web of Science ®Google Scholar
• Botplusweb.portalfarma.com. BOT Plus 2. Base de Datos de Medicamentos [Internet]. Available from: https://botplusweb.portalfarma.com/botplus.aspx/. Accessed March 4, 2022.
   Google Scholar